Codexis, Inc. (NASDAQ:CDXS) Short Interest Update

Codexis, Inc. (NASDAQ:CDXS) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,900,000 shares, an increase of 10.5% from the November 30th total of 1,720,000 shares. Based on an average daily trading volume, of 660,000 shares, the days-to-cover ratio is presently 2.9 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on CDXS shares. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of Codexis in a research note on Friday, November 22nd. Benchmark reissued a “hold” rating on shares of Codexis in a research report on Monday, November 4th.

Institutional Trading of Codexis

A number of hedge funds and other institutional investors have recently made changes to their positions in CDXS. Bank of New York Mellon Corp lifted its position in Codexis by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 284,166 shares of the biotechnology company’s stock valued at $881,000 after purchasing an additional 32,138 shares during the period. Rhumbline Advisers lifted its holdings in shares of Codexis by 3.8% in the 2nd quarter. Rhumbline Advisers now owns 108,594 shares of the biotechnology company’s stock valued at $337,000 after buying an additional 4,017 shares during the period. Private Advisor Group LLC boosted its stake in shares of Codexis by 19.0% in the second quarter. Private Advisor Group LLC now owns 275,241 shares of the biotechnology company’s stock worth $853,000 after buying an additional 43,900 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in Codexis during the second quarter worth about $54,000. Finally, American Century Companies Inc. raised its position in Codexis by 18.9% during the second quarter. American Century Companies Inc. now owns 100,734 shares of the biotechnology company’s stock valued at $312,000 after acquiring an additional 16,019 shares in the last quarter. Institutional investors and hedge funds own 78.54% of the company’s stock.

Codexis Stock Performance

CDXS traded up $0.10 on Wednesday, reaching $4.77. 645,250 shares of the stock were exchanged, compared to its average volume of 568,039. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. The company’s 50-day moving average price is $4.47 and its 200 day moving average price is $3.57. The firm has a market capitalization of $388.17 million, a PE ratio of -5.48 and a beta of 2.15. Codexis has a fifty-two week low of $2.53 and a fifty-two week high of $6.08.

Codexis (NASDAQ:CDXS) last released its earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The firm had revenue of $12.83 million for the quarter, compared to analyst estimates of $11.64 million. During the same period last year, the firm earned ($0.26) EPS. As a group, sell-side analysts forecast that Codexis will post -0.77 EPS for the current fiscal year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.